Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

939 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.
Gong J, Mita AC, Wei Z, Cheng HH, Mitchell EP, Wright JJ, Ivy SP, Wang V, Gray RC, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Alva AS, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Gong J, et al. Among authors: wang v. JCO Precis Oncol. 2024 Apr;8:e2300406. doi: 10.1200/PO.23.00406. JCO Precis Oncol. 2024. PMID: 38603651 Clinical Trial.
The NCI-MATCH trial: lessons for precision oncology.
O'Dwyer PJ, Gray RJ, Flaherty KT, Chen AP, Li S, Wang V, McShane LM, Patton DR, Tricoli JV, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Takebe N, Sims DJ, Coffey B, Fu T, Routbort M, Rubinstein LV, Little RF, Arteaga CL, Marinucci D, Hamilton SR, Conley BA, Harris LN, Doroshow JH. O'Dwyer PJ, et al. Among authors: wang v. Nat Med. 2023 Jun;29(6):1349-1357. doi: 10.1038/s41591-023-02379-4. Epub 2023 Jun 15. Nat Med. 2023. PMID: 37322121 Review.
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
Chen MF, Song Z, Yu HA, Sequist LV, Lovly CM, Mitchell EP, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Umemura Y, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Chen MF, et al. Among authors: wang v. JCO Precis Oncol. 2024 Apr;8:e2300454. doi: 10.1200/PO.23.00454. JCO Precis Oncol. 2024. PMID: 38591867 Clinical Trial.
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
Gong J, Mita AC, Wei Z, Cheng HH, Mitchell EP, Wright JJ, Ivy SP, Wang V, Gray RC, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Gong J, et al. Among authors: wang v. JCO Precis Oncol. 2024 Apr;8:e2300407. doi: 10.1200/PO.23.00407. JCO Precis Oncol. 2024. PMID: 38603650 Clinical Trial.
Cystatin C Use for CKD Detection in the Veterans Health Administration System: A Qualitative Study of Barriers and Facilitators.
Lamprea-Montealegre JA, Shapiro A, Bontrager NAB, Rifkin DE, Jassal SK, Gregg LP, Navaneethan SD, Navarra K, Shlipak MG, Estrella MM, Wang V. Lamprea-Montealegre JA, et al. Among authors: wang v. Kidney Med. 2024 Apr 22;6(6):100830. doi: 10.1016/j.xkme.2024.100830. eCollection 2024 Jun. Kidney Med. 2024. PMID: 38799784 Free PMC article.
939 results